Beat Bornhauser, Gunnar Cario, Anna Rinaldi, Thomas Risch, Virginia Rodriguez Martinez, Moritz Schütte, Hans-Jörg Warnatz, Nastassja Scheidegger, Paulina Mirkowska, Martina Temperli, Claudia Möller, Angela Schumich, Michael Dworzak, Andishe Attarbaschi, Monika Brüggemann, Mathias Ritgen, Ester Mejstrikova, Andreas Hofmann, Barbara Buldini, Pamela Scarparo, Giuseppe Basso, Oscar Maglia, Giuseppe Gaipa, Tessa-Lara Skoblyn, Geertruij Te Kronnie, Elena Vendramini, Renate Panzer-Grümayer, Malwine Jeanette Barz, Blerim Marovca, Mathias Hauri-Hohl, Felix Niggli, Cornelia Eckert, Martin Schrappe, Martin Stanulla, Martin Zimmermann, Bernd Wollscheid, Marie-Laure Yaspo, Jean-Pierre Bourquin
Most relapses of acute lymphoblastic leukemia (ALL) occur in patients with a medium risk (MR) for relapse on the Associazione Italiana di Ematologia e Oncologia Pediatrica and Berlin-Frankfurt-Münster (AIEOP-BFM) ALL protocol, based on persistence of minimal residual disease (MRD). New insights into biological features that are associated with MRD are needed. Here, we identify the glycosylphosphatidylinositol-anchored cell surface protein vanin-2 (VNN2; GPI-80) by charting the cell surface proteome of MRD very high-risk (HR) B-cell precursor (BCP) ALL using a chemoproteomics strategy...
September 8, 2020: Blood Advances